Development of Inactivated Polio Vaccine (IPV) Derived from Attenuated Sabin Strains

Bakker, Wilfried A.M.; Thomassen, Yvonne E.; Oever, Aart G. van 't; Westdijk, Janny; Oijen, Monique G.C.T. van; Kersten, Gideon; Pol, Leo A. van der; Hertroys, Rudy; Heuvel, Nico van den; Hendriks, J.

doi:10.1007/978-94-007-0884-6_105

Cited by 1 publication

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the proof of principle study [ 23 ] in which OPV bulks were obtained to generate IPV, a precipitate was noticed during inactivation. Analysis showed that this precipitate was a phosphate based precipitate without product.…”

Section: Resultsmentioning

confidence: 99%

“…Vero cells from a manufacturers working cell bank were used. Master and working seedlots were prepared from Sabin type 1 LSc 2ab KP 2 (WHO/Beringwerke SO+1, 1976), type 2 P712 Ch2ab-KP 2 (WHO/Behringwerke SO+1, 1976) and type 3 (Pfizer RSO1, SO+5, lot 457-III, 1963; supplied by Institute Mérieux to RIVM in 1991) [ 23 ]. Working seedlots were additionally tested for neurovirulence in monkeys (Bio Farma, Indonesia) [ 24 ] and analyzed with MAPREC (mutant analysis by PCR and restriction enzyme cleavage; NIBSC/HPA, UK) [ 25 ] and RCT40 (replicating properties 36°C- 40°C; AFSSAPS, France) [ 24 ] to assess genetic stability with respect to biosafety ( Table 1 ).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Next Generation Inactivated Polio Vaccine Manufacturing to Support Post Polio-Eradication Biosafety Goals

et al. 2013

Self Cite

View full text Add to dashboard Cite

Worldwide efforts to eradicate polio caused a tipping point in polio vaccination strategies. A switch from the oral polio vaccine, which can cause circulating and virulent vaccine derived polioviruses, to inactivated polio vaccines (IPV) is scheduled. Moreover, a manufacturing process, using attenuated virus strains instead of wild-type polioviruses, is demanded to enhance worldwide production of IPV, especially in low- and middle income countries. Therefore, development of an IPV from attenuated (Sabin) poliovirus strains (sIPV) was pursued. Starting from the current IPV production process based on wild type Salk strains, adaptations, such as lower virus cultivation temperature, were implemented. sIPV was produced at industrial scale followed by formulation of both plain and aluminium adjuvanted sIPV. The final products met the quality criteria, were immunogenic in rats, showed no toxicity in rabbits and could be released for testing in the clinic. Concluding, sIPV was developed to manufacturing scale. The technology can be transferred worldwide to support post polio-eradication biosafety goals.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%